La cadena de opciones muestra datos clave de las opciones de acciones de ZyVersa Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ZyVersa Therapeutics..

ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa, Cadena de Opciones

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

Macro Economic Events

News

Econ #s

Economics

API Weekly Crude Oil Stock Build Of $1.643 Barrels Vs Build Of 0.700M Barrel Est.; Draw Of 1.580M Barrels Prior

WIIM

MTDR

Matador Resources shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 production guidance.

WFRD

Weatherford shares are trading higher following Q3 financial results.

Wheels Up Experience Entered Into Agreement To Acquire Grandview Aviation Entire Fleet Of 17  Phenom 300 And Phenom 300E Aircraft At $105M

VICR

Vicor shares are trading higher after the company reported better-than-expected Q3 financial results.

Stride shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 and Q2 revenue guidance above estimates.

Peapack Gladstone Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGC#NASDAQ">PGC</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.37 by 16.22 percent. This is a 12.24 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $56.62 million which beat the analyst consensus estimate of $56.25 million by 0.66 percent. This is a 1.34 percent increase over sales of $55.87 million the same period last year.

Earnings

Earnings Beats

Peapack Gladstone Finl Q3 EPS $0.43 Beats $0.37 Estimate, Sales $56.62M Beat $56.25M Estimate

FS Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBW#NASDAQ">FSBW</a>) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.14 by 13.16 percent. This is a 14.16 percent increase over earnings of $1.13 per share from the same period last year.

FSBW

FS Bancorp Q3 EPS $1.29 Beats $1.14 Estimate

OCUP

Ocuphire Pharma shares are trading higher after the company announced its new OPGx-LCA5 Phase 1/2 6-month data demonstrated safety and visual improvement in its early onset regional degeneration. Also, the company will seek a strategic partner to continue the development of APX3330.

ANRO

Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.

Southeast Airport Group Q3 2024 GAAP EPS $5.7374 Beats $5.73 Estimate

This closure is part of the Company&rsquo;s Fit to Win initiative to reduce redundant capacity and begin to optimize its network. Additional furnace closures and other restructuring actions are expected later in 2024.
The furnace closure is expected to occur on or after November&nbsp;18, 2024. The Company intends to facilitate the closure in a respectful manner for the approximately 150 people impacted.&nbsp;&nbsp;
Subject to finalization of certain estimates, the Company expects to record a charge associated with this closure of approximately $39 million in the third quarter of 2024.&nbsp; Major components of the charge include approximately $24 million for impairment of plant-related assets, such as the closed furnace and related machinery, and $15 million for one-time employee separation benefits and other costs related to the closing (of which approximately $10 million relate to future cash expenditures).

On October 21, O-I Glass Finalizes Plans For Closure Of A Furnace In Its Americas Segment

Seagate Technology shares are trading lower. The company reported Q1 financial results.

Buybacks

SEIC

SEI Expands Stock Repurchase Program By $400M, Bringing Total Authorization To Approximately $429M

CSGP

CoStar shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Packaging Corp shares are trading higher after the company reported better-than-expected Q3 financial results.

Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.82 by 2.44 percent. The company reported quarterly sales of $195.581 million which beat the analyst consensus estimate of $192.457 million by 1.62 percent. This is a 0.73 percent increase over sales of $194.160 million the same period last year.

TRMK

Trustmark Q3 2024 Adj. EPS $0.84 Beats $0.82 Estimate, Sales $195.581M Beat $192.457M Estimate

Franklin Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRAF#NASDAQ">FRAF</a>) reported quarterly earnings of $0.95 per share. This is a 7.95 percent increase over earnings of $0.88 per share from the same period last year.

FRAF

Franklin Financial Servs Q3 EPS $0.95 Up From $0.88 YoY

Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported its third-quarter financial results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/n41465683/ti-reports-third-quarter-2024-financial-results-and-shareholder-returns">details from the report.&nbsp;</a>
The Details: Texas Instruments reported quarterly earnings of $1.47 per share, which beat the analyst consensus estimate of $1.37. Quarterly revenue of $4.151 billion beat the consensus estimate of $4.12 billion.
&#8220;Industrial continued to decline sequentially, while all other end markets grew. Our cash flow from operations of $6.2 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300mm production. Free cash flow for the same period was $1.5 billion,&#8221; said Haviv Ilan, CEO of Texas Instruments.
&#8220;Over the past 12 months we invested $3.7 billion in R&amp;D and SG&amp;A, invested $4.8 billion in capital expenditures and returned $5.2 billion to owners,&#8221; Ilan added.
Read Next: <a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a>
Outlook: Texas Instruments sees fourth-quarter earnings between $1.07 and $1.29 per share, versus the $1.34 estimate and quarterly revenue in a range of $3.7 billion to $4 billion, versus the $4.07 billion consensus estimate. 
TXN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Texas Instruments shares are seesawing after the close, but at publication on Tuesday were up 0.015% at $194.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a></li>
</ul>
Photo: Shutterstock&nbsp;

After-Hours Center

Movers

Tech

Texas Instruments Shares Seesaw After Q3 Results Beat Estimates, Weak Q4 Guidance

The First Bancshares, Inc. ("The First") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBMS#NYSE">FBMS</a>), holding company for The First Bank, (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.thefirstbank.com&amp;esheet=54140569&amp;newsitemid=20241022552905&amp;lan=en-US&amp;anchor=www.thefirstbank.com&amp;index=1&amp;md5=48fd2241736b076ad99d73a53a69831d">www.thefirstbank.com</a>), announced today that the previously announced merger between The First and Renasant Corporation ("Renasant"), pursuant to the Agreement and Plan of Merger, dated as of July 29, 2024, (the "Merger Agreement"), has been approved by its shareholders. Completion of the transaction remains subject to customary closing conditions, including the receipt of required regulatory approvals.

FBMS

The First Bancshares Announces Receipt Of Shareholder Approval For Merger

PHG, IBRX and MESO are among premarket gainers

ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers

CRVS, CTMX and NRXP are among premarket  gainers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) just reported results for the first quarter of 2024.<ul><li>ZyVersa Therapeutics reported earnings per share of -$4.53. This was below the analyst estimate for EPS of -$3.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/zvsa-stock-earnings-zyversa-therapeutics-for-q1-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024

ZyVersa Therapeutics GAAP EPS of -$4.53 misses by $0.78

ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) just reported results for the second quarter of 2024.<ul><li>ZyVersa Therapeutics reported earnings per share of -$3.31. This was above the analyst estimate for EPS of -$3.75.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/zvsa-stock-earnings-zyversa-therapeutics-for-q2-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024

ZyVersa Therapeutics files for mixed shelf offering

Warning: ZVSA is at high risk of performing badly

ABVC

ADXN

AGBA

AQST

ATXI

BENF

CJJD

CLVR

DCPH

HOLO

HSAI

IBRX

ICLK

IMTE

INCR

MESO

NITO

NIVF

NUVO

OPTN

SLNO

SWIN

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

Biotech

General

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Press Releases

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

Health Care

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Analyst Ratings

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Comments

ZyVersa Therapeutics

ZyVersa Therapeutics (ZVSA) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL